Kyverna Therapeutics, Inc. (KYTX) News
Follow Kyverna Therapeutics, Inc. (KYTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 16 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Weekly Recap: 12—month SPS durability and $500—$600K pricing plan
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) reported 12—month durability and good safety for SPS in generalized myasthenia gravis with no high—grade CRS/ICANS, CEO Warner Biddle says stronger—than—expected durability suppor
NEWS | Sep 28, 2026, 11:04 AM UTC
L
KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price
Shares of Kyverna Therapeutics (KYTX) fell on Thursday even after the company reported that a one-time cell therapy kept helping patients with stiff person syndrome (SPS) and generalized myasthenia gravis a full year lat
EQUITY | Sep 24, 2026, 06:29 PM UTC
L
Kyverna Therapeutics reports positive one-year miv-cel data in SPS; rolling BLA on track for Q4
Kyverna Therapeutics reported positive one-year durability and safety data for miv-cel in stiff person syndrome and longer-term Phase 2 follow-up in generalized myasthenia gravis.Key Highlights:Original SEC Filing: Kyver
REGULATION | Sep 24, 2026, 10:03 AM UTC
L
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
Topline durability data reinforce potential for single-dose miv-cel to free patients from life-long disease burden and chronic immunotherapies, further highlighting miv-cel’s differentiated constructSustained clinical be
NEWS | Sep 24, 2026, 10:02 AM UTC
L
Kyverna Therapeutics, Inc. (KYTX) Reports 1-Year Durable Responses for Miv-cel in SPS, gMG
Kyverna reported positive 12-month durability and safety data for miv-cel in SPS, supporting a rolling BLA targeted for completion in Q4 2026, and longer-term Phase 2 follow-up in gMG showing robust, durable effects up t
NEWS | Sep 24, 2026, 10:01 AM UTC
L
KYTX - Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
KYTX - Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
NEWS | Sep 24, 2026, 10:00 AM UTC
L
KYTX: Miv-cel shows transformative results in SPS and gMG, with regulatory and commercial milestones ahead
Transformative cell therapy miv-cel is advancing toward regulatory approval for Stiff Person Syndrome, with strong safety and efficacy data and a rolling BLA submission expected to complete in Q4. Expansion into gMG and
NEWS | Sep 15, 2026, 04:54 PM UTC
L
KYTX: miv-cel nears approval for SPS, with strong safety, efficacy, and expansion into gMG and MS
Transformative cell therapy miv-cel is advancing toward regulatory approval for SPS, showing strong safety and efficacy, with plans to expand into gMG and MS. High demand and premium pricing are anticipated, supported by
NEWS | Sep 15, 2026, 04:30 PM UTC
L
KYTX: Transformative cell therapy shows strong efficacy and safety, targeting near-term approval and launch
Cell therapy for autoimmune diseases is advancing rapidly, with miv-cel showing strong efficacy and safety in stiff person syndrome and myasthenia gravis. Regulatory progress, robust clinical data, and a focused commerci
NEWS | Sep 14, 2026, 09:22 PM UTC
L
KYTX: Transformative cell therapy shows durable efficacy and safety in multiple autoimmune diseases
Cell therapy for autoimmune diseases is advancing rapidly, with miv-cel showing strong efficacy and safety in stiff person syndrome, myasthenia gravis, and progressive MS. Regulatory progress, robust physician support, a
NEWS | Sep 14, 2026, 09:15 PM UTC
L
KYTX: Miv-cel shows unprecedented efficacy in SPS, with regulatory and commercial milestones set for 2027
Transformative clinical results for miv-cel in SPS and MG drive regulatory progress, with a rolling BLA for SPS on track for Q4 completion and launch readiness in 2027. Manufacturing innovations and focused commercializa
EQUITY | Sep 09, 2026, 09:43 PM UTC
L
KYTX - Kyverna Therapeutics to Present at Upcoming Investor Conferences
KYTX - Kyverna Therapeutics to Present at Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 08:07 PM UTC
L
Kyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) Estimate
Kyverna Therapeutics (NASDAQ: KYTX ) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.68) by 7.35 percent. This is a 35.05 percent increase over losses of $(0.97) per share
EARNINGS | Aug 11, 2026, 08:18 PM UTC
L
KYTX - Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
KYTX - Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
EARNINGS | Aug 11, 2026, 08:02 PM UTC
L
KYTX Kyverna Therapeutics and elevatebio enter into commercial manufacturing and supply agreement for miv-cel Kyverna Therapeutics - agreeme
KYTX Kyverna Therapeutics and elevatebio enter into commercial manufacturing and supply agreement for miv-cel Kyverna Therapeutics - agreement provides scalable miv-cel supply for potential Sps and gmg launches - On trac
EQUITY | Jul 27, 2026, 12:01 PM UTC
L
KYTX Appoints Chief Legal Officer
Kyverna Therapeutics appoints Ritesh Srivastava as Chief Legal and Compliance Officer to support commercial-stage transition
EQUITY | Jun 22, 2026, 12:01 PM UTC